Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (511-520 of 602) with videos related to

Pageof 61
Sort By:
Blood Cancer Journal|August 13, 2020
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseNadine Abdallah, S Vincent Rajkumar, Patricia Greipp, et al.
American Journal of Hematology|April 5, 2019
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapyMarcella A Tschautscher, Dragan Jevremovic, Vincent Rajkumar, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Cancer|November 22, 2022
Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myelomaBharat Nandakumar, Francis Baffour, Nadine H Abdallah, et al.
American Journal of Hematology|December 24, 2019
Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cellsWilson I Gonsalves, Dragan Jevremovic, Bharat Nandakumar, et al.
Pageof 61

Showing results (511-520 of 602) with videos related to

Sort By:
Pageof 61
Blood Cancer Journal|August 13, 2020
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseNadine Abdallah, S Vincent Rajkumar, Patricia Greipp, et al.
American Journal of Hematology|April 5, 2019
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapyMarcella A Tschautscher, Dragan Jevremovic, Vincent Rajkumar, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Cancer|November 22, 2022
Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myelomaBharat Nandakumar, Francis Baffour, Nadine H Abdallah, et al.
American Journal of Hematology|December 24, 2019
Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cellsWilson I Gonsalves, Dragan Jevremovic, Bharat Nandakumar, et al.
Pageof 61